Murray Stewart
Director/Board Member at X4 PHARMACEUTICALS, INC.
Net worth: 165 550 $ as of 2024-04-29
Profile
Murray Willis Stewart is currently a Director at X4 Pharmaceuticals, Inc., a Director at Vivli Center For Global Clinical Research Data, and a Director at VectivBio AG.
Previously, he served as an Independent Director at Amarin Corp.
Plc, an Independent Director at VectivBio Holding AG, the Chief Medical Officer at Rhythm Pharmaceuticals, Inc., the Chief Medical Officer at GSK Plc, and the Executive VP, Head-Research & Development at Novelion Therapeutics, Inc. Dr. Stewart holds a doctorate degree from The University of Southampton.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
X4 PHARMACEUTICALS, INC.
0.09% | 2023-08-09 | 146,504 ( 0.09% ) | 165 550 $ | 2024-04-29 |
Murray Stewart active positions
| Companies | Position | Start |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Director/Board Member | 2019-03-28 |
| Vivli Center For Global Clinical Research Data | Director/Board Member | - |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Director/Board Member | - |
Former positions of Murray Stewart
| Companies | Position | End |
|---|---|---|
| VECTIVBIO HOLDING AG | Director/Board Member | 2023-06-25 |
| AMARIN CORPORATION PLC | Director/Board Member | 2023-03-05 |
| RHYTHM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2021-09-09 |
| NOVELION THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 2018-10-16 |
| GSK PLC | Chief Tech/Sci/R&D Officer | 2017-10-31 |
Training of Murray Stewart
| The University of Southampton | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| AMARIN CORPORATION PLC | Health Technology |
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| GSK PLC | Health Technology |
| Private companies | 5 |
|---|---|
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
| X4 Pharmaceuticals, Inc. | |
| Vivli Center For Global Clinical Research Data | |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Murray Stewart